Biovation And Viventia Biotech Form Collaboration To Design A Novel Non-Immunogenic Protein Therapeutic
11-Dec-2002 -
Darmstadt, Germany - Biovation Ltd. of Aberdeen, UK, and Viventia Biotech,
Inc., of Toronto, Canada, today announce the signing of a research
agreement under which Biovation will apply its proprietary technology,
DeImmunisation, to one of Viventia's novel cytotoxic proteins. Biovation
will ...
amino acids
antibodies
Germany
+3